Published in Cancer Weekly, March 8th, 1999
T.K. Nikula and colleagues from the Memorial Sloan Kettering Cancer Center, New York, described the pharmacokinetic, bioactivity, toxicity and chemical characteristics of cr-particle-emitting, Bi-213 and Bi-212 radiometal conjugated HuM195 (anti-CD33) constructs ("Alpha-Emitting Bismuth Cyclohexylbenzyl DTPA"Alpha-Emitting Bismuth Cyclohexylbenzyl DTPA Constructs of Recombinant Humanized Anti-CD33 Antibodies: Pharmacokinetics, Bioactivity, Toxicity and Chemistry," Journal of Nuclear Medicine, January 1999;40(1):166-176).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.